Andrew S. Wells

发表

Case Studies Illustrating a Science and Risk-Based Approach to Ensuring Drug Quality When Using Enzymes in the Manufacture of Active Pharmaceuticals Ingredients for Oral Dosage Form

Long Pang, Timothy J. Watson, Thomas S. Moody, 2016 .

The Development of a Manufacturing Route for the GPIIb/IIIa Receptor Antagonist SB-214857-A. Part 2: Conversion of the Key Intermediate SB-235349 to SB-214857-A

Gary Francis GlaxoSmithKline Breen, A. Wells, J. S. Carey, 2003 .

Efficient Synthesis of (S)-1-(5-Fluoropyrimidin-2-yl)ethylamine Using an ω-Transaminase Biocatalyst in a Two-Phase System

Oliver May, Daniel Mink, Christopher John Squire, 2013 .

Continuous Processing in the Pharmaceutical Industry

Joel M. Hawkins, Peter J. Dunn, A. Wells, 2010 .

Green chemistry in the pharmaceutical industry

Peter J. Dunn, A. Wells, M. T. Williams, 2010 .

Survey of Solvent Usage in Papers Published in Organic Process Research & Development 1997–2012

John D. Hayler, Peter J. Dunn, A. Wells, 2015 .

Use of Enzymes in the Manufacture of Active Pharmaceutical Ingredients—A Science and Safety-Based Approach To Ensure Patient Safety and Drug Quality

Gregory L. Finch, A. Wells, G. Finch, 2012 .

Use of ω-Transaminase Enzyme Chemistry in the Synthesis of a JAK2 Kinase Inhibitor

Christopher John Squire, David J. Klauber, Kevin William Leslie, 2013 .